POP Biotechnologies announces formation of joint venture, EUPOP Life Sciences, in collaboration with South Korean collaborator, Eubiologics, Co., Ltd.

POP Biotechnologies (POP BIO) is pleased to announce the formation of a joint venture, EUPOP Life Sciences, located in Buffalo, NY, in collaboration with South Korean vaccine manufacturer EuBiologics Co., Ltd. The formation of this new life sciences venture is concurrent with a previously-announced multi-million-dollar investment from EuBiologics in POP BIO.

„Lorem modi tempora incidunt ut labore et dolore magnam.”

– Marcus Pervetti

EUPOP will leverage POP BIO’s Spontaneous Nanoliposome Antigen Particleization (SNAP) vaccine platform technology, which enables rapid and streamlined generation of highly immunogenic nanoparticle vaccines, together with EuBiologics’ complementary immune enhancing EuIMT technology for the development of a series of vaccine candidates directed at respiratory syncytial virus (RSV), shingles, and Alzheimer’s disease.

In addition to the formation of EUPOP, POP BIO and EuBiologics are collaborating to address the unprecedented COVID-19 global pandemic. Supported by strong preclinical data, the two companies are combining their unique technologies to develop a highly immunogenic nanoparticle vaccine against SARS-CoV-2.